Hexavalent bovine rotavirus reassortant composition designed for use in developing countries

US8168202B2 · kind B2 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• Albert Z. Kapikian · Rockville, US
• Lone Simonsen · Bethesda, US
• Timo Vesikari · Tampere, FI
• Yasutaka Hoshino · Wheaton, US
• David M. Morens · Bethesda, US
• Robert M. Chanock · Bethesda, US
• John R. La Montagne · Alexandria, US
• Brian R. Murphy · Bethesda, US

Key dates

• Filing date: Jul 7, 2006
• Grant date: May 1, 2012
• Expiry date: Jul 15, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2720/12334
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human× bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.